Keywords
salivary biopsy
ESSDAI
How to Cite
Abstract
Introduction: Sjögren's disease is a common autoimmune disorder characterized by chronic lymphocytic infiltration of exocrine glands and various extraglandular systemic manifestations. While most patients are seropositive (with anti-Ro/SSA and anti-La/SSB antibodies), there is a significant seronegative subgroup that lacks these markers. In this group, minor salivary gland biopsy becomes an essential diagnostic tool.
Objectives: To evaluate the usefulness of minor salivary gland biopsy (MSBG) in the diagnosis of Sjögren's disease in patients with a high clinical suspicion but negative autoantibodies, and to characterize its clinical manifestations, complete serological profile, and disease activity level using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).
Materials and methods: A retrospective, cross-sectional, analytical, observational study was conducted, including patients over 18 years of age with suspected Sjögren's disease and negative autoantibodies referred for minor salivary gland biopsy (MSBG) between January 2023 and January 2025. Data collection was based on electronic medical records, pathology reports, and serological profiles (ANA, Anti-Ro/SSA, Anti-La/SSB). The main objective was to evaluate the usefulness of minor salivary gland biopsy (MSGB) (using the focus score ) and to characterize disease activity using the ESSDAI score. Statistical analysis of the data was performed using IBM SPSS software version 30.0.0.
Results: Seven female patients were included, with a mean age of 44.71 years (SD ± 13.21). Clinically, 100% reported xerophthalmia and 71.4% xerostomia, although objective functional tests (Schirmer test) were negative in all cases. Minor salivary gland biopsy (MSGB) was positive (focus score ≥ 1) in 6 of 7 patients (85.7%), with a mean focus score of 2.14 (SD ± 1.574). Despite the initial remission, serological analysis reclassified 4 patients (57.1%) as seropositive (anti-Ro/SSA and/or anti-La/SSB positive), leaving 3 patients (42.9%) as true seronegatives. The overall disease activity, as measured by the ESSDAI, was 7.14 (SD ± 7.081), with the glandular domain being the most prevalent and exhibiting the highest activity burden (mean 2.29).
Conclusion: Minor salivary gland biopsy is a valuable diagnostic tool in the seronegative patient group. Disease activity, as measured by the ESSDAI, was predominantly concentrated in the glandular domain.
References
(1) Reed JH, Verstappen GM, Rischmueller M, Bryant VL. When B cells break bad: development of pathogenic B cells in Sjögren's syndrome. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):271-282.
(2) Lee AYS, Rischmueller M, Reed JH. Seronegative Sjögren Syndrome: A Forgotten Entity? J Rheumatol. enero de 2024;51(1):7-9.
(3) Barone F, Campos J, Bowman S, Fisher BA. The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjögren’s Syndrome. Swiss Med Wkly. 6 de septiembre de 2015;145(3738):w14168.
(4) Chatzis LG, Pezoulas V, Voulgari PV, Baldini C, Exarchos TP, Fotiadis DI, et al. Combined seronegativity in Sjögren’s syndrome. Clinical and Experimental Rheumatology. 15 de diciembre de 2021;39(6):80-4.
(5) Mariette X, Criswell LA. Primary Sjögren’s Syndrome. Solomon CG, editor. N Engl J Med. 8 de marzo de 2018;378(10):931-9.
(6) Hoshina Y, Wong KH, Galli J, Bacharach R, Klein J, Lebiedz-Odrobina D, et al. Neurologic involvement in seronegative primary Sjögren’s syndrome with positive minor salivary gland biopsy: a single-center experience. Front Neurol. 9 de junio de 2023;14:1174116.
(7) García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren Syndrome: Clinical and Immunologic Disease Patterns in a Cohort of 400 Patients. Medicine. julio de 2002;81(4):270-80.
(8) Daniels TE, Cox D, Shiboski CH, Schiødt M, Wu A, Lanfranchi H, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. Arthritis Rheum. 2011 Jul;63(7):2021-30. doi: 10.1002/art.30381.
(9) Berardicurti O, Ruscitti P, Di Benedetto P, D’Andrea S, Navarini L, Marino A, et al. Association Between Minor Salivary Gland Biopsy During Sjӧgren’s Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. Front Immunol. 11 de junio de 2021;12:686457.
(10) Lamos-Duarte AF, Parra-Medina R, Rivadeneira-Chamorro CS, Castañeda-González JP, Escobar A, Rojas-Villarraga A, et al. Características clínicas, histopatológicas e inmunohistoquímicas de pacientes con síndrome seco y biopsia de glándula salival con puntaje de foco de 1 o más. Biomed. 28 de marzo de 2025;45(1):80-93.
(11) Fischer A, Swigris JJ, Du Bois RM, Groshong SD, Cool CD, Sahin H, et al. Minor Salivary Gland Biopsy To Detect Primary Sjögren Syndrome in Patients With Interstitial Lung Disease. Chest. octubre de 2009;136(4):1072-8.
(12) Gamze Erkılınç, Atalay Doğru, Yaşar Arslan, Rıza Burak Öz, Nermin Karahan, Mehmet Şahin, et al. Evaluation of histopathological results of minor salivary gland biopsies in patients with the diagnosis of Sjögren’s syndrome. Archives of Rheumatology. 31 de marzo de 2022;37(1):049-58.
(13) Pijpe J, Kalk WWI, Van Der Wal JE, Vissink A, Kluin PhM, Roodenburg JLN, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren’s syndrome. Rheumatology. 28 de julio de 2006;46(2):335-41.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Laura Martínez, Marcos A. Vázquez